when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

309 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT824 Endpoints627 BioPharma Dive239 onclive165 Fierce Biotech91 BioSpace90 raps32 globenewswire health28

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology

FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
onclive · 2mo ago↗ source
UT MD Anderson Shares Latest Research Breakthroughs
The University of Texas MD Anderson Cancer Center released recent oncology research highlights.
onclive · 2mo ago↗ source
Giants of Cancer Care Announces the 14th Annual Class of Inductees
onclive · 2mo ago↗ source

page 11 of 13

6

Infectious Disease4

OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

onclive · 2mo ago↗ source

OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026

Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

onclive · 2mo ago↗ source

Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

onclive · 2mo ago↗ source

Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL

Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.

onclive · 2mo ago↗ source

The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer

Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patien…

onclive · 2mo ago↗ source

Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study

This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequ…

onclive · 2mo ago↗ source

First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

onclive · 2mo ago↗ source

Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability

This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and strategies…

onclive · 2mo ago↗ source

Dr Sznol on Optimal Treatment Sequencing in Melanoma

Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.

onclive · 2mo ago↗ source

Mentorship Is Key to Advance the Next Generation of Oncology Researchers

Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators.

onclive · 2mo ago↗ source

Dr Mauro on the Significance of Alternative TKI Formulations in CML

Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.

onclive · 2mo ago↗ source

Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn

Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.

onclive · 2mo ago↗ source

Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC

Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.

onclive · 2mo ago↗ source

Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer

Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.

onclive · 2mo ago↗ source

Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.

Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.

onclive · 2mo ago↗ source

FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease

The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.

onclive · 2mo ago↗ source

ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

onclive · 2mo ago↗ source

Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026

Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.

onclive · 2mo ago↗ source

EGFR-Targeted Therapy Sequencing After Resistance in NSCLC

Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.

onclive · 2mo ago↗ source

HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations

Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.

onclive · 2mo ago↗ source

Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.

onclive · 2mo ago↗ source

Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA

Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.

onclive · 2mo ago↗ source